Q: Warnings?

• Before administration, the solution should be inspected. The solution may contain trace amount of translucent to white proteinaceous particles. Do not inject the solution if it contains particles, or is cloudy or discoloured. • Do not shake. • To avoid discomfort at the site of injection, allow the pre-filled syringe to reach room temperature (up to 25 °C) before injecting and

Question 1

Indications?

Accepted Answer

1 INDICATIONS AND USAGE Conexxence is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture rec

Question 2

Dosage?

Accepted Answer

CONEXXENCE: Roztwór do wstrzykiwań 120 mg

Question 3

Side Effects?

Accepted Answer

6 ADVERSE REACTIONS The following serious adverse reactions are discussed below and also elsewhere in the labeling: Severe Hypocalcemia and Mineral Metabolism Changes [see Warnings and Precautions ( 5.1 )] Hypersensitivity [see Warnings and Precautions ( 5.3 )] Osteonecrosis of the Jaw [see Warnings and Precautions ( 5.4 )] Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings an

Question 4

Contraindications?

Accepted Answer

4 CONTRAINDICATIONS Conexxence is contraindicated in: Patients with hypocalcemia: Pre-existing hypocalcemia must be corrected prior to initiating therapy with Conexxence [see Warnings and Precautions ( 5.1 )] .﻿‍​‍‍‍​‍‍‍‍‍‍‍‍​‍﻿ Pregnant women: Denosumab products may cause fetal harm when administered to a pregnant woman. In women of reproductive potential, pregnancy testing should be performed pr

Question 5

Warnings?

Accepted Answer

• Before administration, the solution should be inspected.﻿‍​‍‍‍​‍‍‍‍‍‍‍‍​‍﻿ The solution may contain trace amount of translucent to white proteinaceous particles. Do not inject the solution if it contains particles, or is cloudy or discoloured.
• Do not shake.
• To avoid discomfort at the site of injection, allow the pre-filled syringe to reach room temperature (up to 25 °C) before injecting and

CONEXXENCE

User Reviews